MMP-14 and CD44 in Epithelial-to-Mesenchymal Transition (EMT) in ovarian cancer

M.C. Vos, E. Hollemans, N.P.M. Ezendam, H. Feijen, D. Boll, B. Pijlman, H. van der Putten, P. Klinkhamer, T.H. Kuppevelt, A.A. van de Wurff, L.F. Massuger

Research output: Contribution to journalArticleScientificpeer-review

29 Citations (Scopus)
92 Downloads (Pure)

Abstract

Background
To investigate the expression of MMP-14 and CD44 as well as epithelial-to-mesenchymal transition(EMT)-like changes in ovarian cancer and to determine correlations with clinical outcome.
Methods
In 97 patients with ovarian cancer, MMP-14 and CD44 expression as determined by immunohistochemistry was investigated in relation to EMT-like changes. To determine this, immunohistochemical staining of E-cadherin and vimentin was performed.
Results
Patients with expression of both MMP-14 and CD44 in their tumors had a poor prognosis despite complete debulking. Serous histology in advanced-stage tumors (FIGO IIB-IV) correlated with CD44 (rho .286, p < 0.01). Also, CD44 correlated with percentage vimentin expression (rho .217, p < 0.05).In logistic regression analysis with complete debulking as the outcome parameter, CD44 expression was found to be significant (OR 3,571 (95 % Confidence Interval 1,112–11,468) p = 0.032), though this was not the case for MMP-14 and EMT parameters.
Conclusion
The subgroup of patients with double expression of MMP-14 and CD44 had a poor prognosis despite complete debulking. Serous subtype in advanced-stage patients and CD44 expression were found to be correlated with vimentin expression, and CD44 expression was found to be significantly correlated with complete debulking. However, a significant correlation between EMT and clinical parameters was not found.KeywordsMMP-14, CD44, Epithelial-to-mesenchymal transition, Ovarian cancer
Original languageEnglish
Article number53
JournalJournal of Ovarian Research
Volume9
Issue number1
DOIs
Publication statusPublished - 2 Sept 2016

Fingerprint

Dive into the research topics of 'MMP-14 and CD44 in Epithelial-to-Mesenchymal Transition (EMT) in ovarian cancer'. Together they form a unique fingerprint.

Cite this